Clinical efficacy and mechanism-of-action of recombinant IFNα-2b, and IFNα-2b in combination with γ-D-glutamyl-L-tryptophan, in chronic polypous rhinosinusitis with comorbid bronchial asthma

Known methods of treating chronic polypous rhinosinusitis do not have a significant effect on the progressive nature of the disease. Recently, anticytokine therapy has been developed and introduced. However, the high cost of drugs and the complexity of their production make it necessary to search fo...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Bezrukova, E. A. Varyushina, M. A. Aflitonov, S. A. Artyushkin, A. S. Simbirtsev
Format: Article
Language:Russian
Published: St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2024-07-01
Series:Медицинская иммунология
Subjects:
Online Access:https://www.mimmun.ru/mimmun/article/view/3060
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849240715963400192
author E. V. Bezrukova
E. A. Varyushina
M. A. Aflitonov
S. A. Artyushkin
A. S. Simbirtsev
author_facet E. V. Bezrukova
E. A. Varyushina
M. A. Aflitonov
S. A. Artyushkin
A. S. Simbirtsev
author_sort E. V. Bezrukova
collection DOAJ
description Known methods of treating chronic polypous rhinosinusitis do not have a significant effect on the progressive nature of the disease. Recently, anticytokine therapy has been developed and introduced. However, the high cost of drugs and the complexity of their production make it necessary to search for other drugs with similar mechanisms of action. Such immunotropic drugs can be recombinant IFNα-2b and the γ-D-glutamyl-L-tryptophan. The aim of the study is to study the mechanism of action and evaluate the effectiveness of local application of IFNα-2b and γ-D-glutamyl-L-tryptophan in chronic polypous rhinosinusitis with concomitant bronchial asthma. Patients of the first group (31 people) were injected with IFNα-2b at a dose of 1 million units into the polypous tissue for five days. Patients of the second group (31 people) were injected with IFNα-2b at a dose of 1 million units and γ-D-glutamyl-L-tryptophan at a dose of 0.1 mg into the polypous tissue for five days. Patients were observed for a year. Before treatment and 1 month after treatment, a biopsy of polypous tissue was performed with analysis of morphological changes. Local administration of IFNα-2b and its combination with the γ-D-glutamyl-L-tryptophan into polypous tissue causes a decrease in the activity of T2 inflammation: decreased intercellular edema, tissue compaction, decreased the number of lymphocytes, eosinophils, plasma cells infiltrating the mucous membrane of polypous tissue. An analysis of the study results based on an assessment of the size of polyps showed that a month after therapy, the size of the polyps decreased, and when using IFNα-2b with γ-D-glutamyl-L-tryptophan, the size of the polyps decreased by approximately 70%, and the use only recombinant IFNα-2b by 40%. After 6 months, there was an increase in polyp tissue by 10-20% compared to the values after 1 month. After a year, the growth of polyps remained at the level of the values obtained after 6 months. The use of both IFNα-2b, and its combination with the γ-D-glutamyl-L-tryptophan, is a pathogenetically substantiated method of treating chronic polyposis rhinosinusitis, which allows its use as a conservative therapy for this disease.
format Article
id doaj-art-2c3784d5bfc2445fb5690c9042f998f5
institution Kabale University
issn 1563-0625
2313-741X
language Russian
publishDate 2024-07-01
publisher St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
record_format Article
series Медицинская иммунология
spelling doaj-art-2c3784d5bfc2445fb5690c9042f998f52025-08-20T04:00:27ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2024-07-0126486187210.15789/1563-0625-CEA-166921919Clinical efficacy and mechanism-of-action of recombinant IFNα-2b, and IFNα-2b in combination with γ-D-glutamyl-L-tryptophan, in chronic polypous rhinosinusitis with comorbid bronchial asthmaE. V. Bezrukova0E. A. Varyushina1M. A. Aflitonov2S. A. Artyushkin3A. S. Simbirtsev4I. Mechnikov North-Western State Medical UniversityA. Smorodintsev Research Institute of InfluenzaLeningrad Regional Clinical HospitalI. Mechnikov North-Western State Medical UniversityState Research Institute of High Pure BiopreparationsKnown methods of treating chronic polypous rhinosinusitis do not have a significant effect on the progressive nature of the disease. Recently, anticytokine therapy has been developed and introduced. However, the high cost of drugs and the complexity of their production make it necessary to search for other drugs with similar mechanisms of action. Such immunotropic drugs can be recombinant IFNα-2b and the γ-D-glutamyl-L-tryptophan. The aim of the study is to study the mechanism of action and evaluate the effectiveness of local application of IFNα-2b and γ-D-glutamyl-L-tryptophan in chronic polypous rhinosinusitis with concomitant bronchial asthma. Patients of the first group (31 people) were injected with IFNα-2b at a dose of 1 million units into the polypous tissue for five days. Patients of the second group (31 people) were injected with IFNα-2b at a dose of 1 million units and γ-D-glutamyl-L-tryptophan at a dose of 0.1 mg into the polypous tissue for five days. Patients were observed for a year. Before treatment and 1 month after treatment, a biopsy of polypous tissue was performed with analysis of morphological changes. Local administration of IFNα-2b and its combination with the γ-D-glutamyl-L-tryptophan into polypous tissue causes a decrease in the activity of T2 inflammation: decreased intercellular edema, tissue compaction, decreased the number of lymphocytes, eosinophils, plasma cells infiltrating the mucous membrane of polypous tissue. An analysis of the study results based on an assessment of the size of polyps showed that a month after therapy, the size of the polyps decreased, and when using IFNα-2b with γ-D-glutamyl-L-tryptophan, the size of the polyps decreased by approximately 70%, and the use only recombinant IFNα-2b by 40%. After 6 months, there was an increase in polyp tissue by 10-20% compared to the values after 1 month. After a year, the growth of polyps remained at the level of the values obtained after 6 months. The use of both IFNα-2b, and its combination with the γ-D-glutamyl-L-tryptophan, is a pathogenetically substantiated method of treating chronic polyposis rhinosinusitis, which allows its use as a conservative therapy for this disease.https://www.mimmun.ru/mimmun/article/view/3060recombinant ifnα-2bγ-d-glutamyl-l-tryptophanchronic polypous rhinosinusitisbronchial asthmaaverage cytochemical coefficientthiol disulfide coefficientaverage destruction indexcell cytolysis index
spellingShingle E. V. Bezrukova
E. A. Varyushina
M. A. Aflitonov
S. A. Artyushkin
A. S. Simbirtsev
Clinical efficacy and mechanism-of-action of recombinant IFNα-2b, and IFNα-2b in combination with γ-D-glutamyl-L-tryptophan, in chronic polypous rhinosinusitis with comorbid bronchial asthma
Медицинская иммунология
recombinant ifnα-2b
γ-d-glutamyl-l-tryptophan
chronic polypous rhinosinusitis
bronchial asthma
average cytochemical coefficient
thiol disulfide coefficient
average destruction index
cell cytolysis index
title Clinical efficacy and mechanism-of-action of recombinant IFNα-2b, and IFNα-2b in combination with γ-D-glutamyl-L-tryptophan, in chronic polypous rhinosinusitis with comorbid bronchial asthma
title_full Clinical efficacy and mechanism-of-action of recombinant IFNα-2b, and IFNα-2b in combination with γ-D-glutamyl-L-tryptophan, in chronic polypous rhinosinusitis with comorbid bronchial asthma
title_fullStr Clinical efficacy and mechanism-of-action of recombinant IFNα-2b, and IFNα-2b in combination with γ-D-glutamyl-L-tryptophan, in chronic polypous rhinosinusitis with comorbid bronchial asthma
title_full_unstemmed Clinical efficacy and mechanism-of-action of recombinant IFNα-2b, and IFNα-2b in combination with γ-D-glutamyl-L-tryptophan, in chronic polypous rhinosinusitis with comorbid bronchial asthma
title_short Clinical efficacy and mechanism-of-action of recombinant IFNα-2b, and IFNα-2b in combination with γ-D-glutamyl-L-tryptophan, in chronic polypous rhinosinusitis with comorbid bronchial asthma
title_sort clinical efficacy and mechanism of action of recombinant ifnα 2b and ifnα 2b in combination with γ d glutamyl l tryptophan in chronic polypous rhinosinusitis with comorbid bronchial asthma
topic recombinant ifnα-2b
γ-d-glutamyl-l-tryptophan
chronic polypous rhinosinusitis
bronchial asthma
average cytochemical coefficient
thiol disulfide coefficient
average destruction index
cell cytolysis index
url https://www.mimmun.ru/mimmun/article/view/3060
work_keys_str_mv AT evbezrukova clinicalefficacyandmechanismofactionofrecombinantifna2bandifna2bincombinationwithgdglutamylltryptophaninchronicpolypousrhinosinusitiswithcomorbidbronchialasthma
AT eavaryushina clinicalefficacyandmechanismofactionofrecombinantifna2bandifna2bincombinationwithgdglutamylltryptophaninchronicpolypousrhinosinusitiswithcomorbidbronchialasthma
AT maaflitonov clinicalefficacyandmechanismofactionofrecombinantifna2bandifna2bincombinationwithgdglutamylltryptophaninchronicpolypousrhinosinusitiswithcomorbidbronchialasthma
AT saartyushkin clinicalefficacyandmechanismofactionofrecombinantifna2bandifna2bincombinationwithgdglutamylltryptophaninchronicpolypousrhinosinusitiswithcomorbidbronchialasthma
AT assimbirtsev clinicalefficacyandmechanismofactionofrecombinantifna2bandifna2bincombinationwithgdglutamylltryptophaninchronicpolypousrhinosinusitiswithcomorbidbronchialasthma